Co-carcinogenic effect of sulphasalazine
1993
Concerns About Sulphasalazine and Cancer Risk
Commentary
Author Information
Author(s): John Meenan
Primary Institution: Academic Medical Centre
Hypothesis
Is sulphasalazine co-carcinogenic in the context of inflammatory bowel disease treatment?
Conclusion
The study suggests that the anti-folate effect of sulphasalazine may not be a justified concern regarding its co-carcinogenic potential.
Supporting Evidence
- The study by Davis et al. raises concerns about the cancer risk of drugs used for inflammatory bowel disease.
- Evidence for local folate deficiency as a cancer risk factor has not been conclusively demonstrated.
- Human colon cells can absorb folate from the diet, which may counteract the effects of sulphasalazine.
Takeaway
Some medicines for gut problems might cause cancer, but we need to look into it more before blaming them.
Limitations
The commentary points out that the evidence for local folate deficiency causing cancer is not well demonstrated.
Want to read the original?
Access the complete publication on the publisher's website